¿Cómo paga?

Cómo pagar lo menos posible

Pregunte el precio sin seguro

Keytruda Qlex

Keytruda Qlex es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

Qué hacer

  1. Pregunte en su farmacia el precio sin seguro de Keytruda Qlex, y también en una o dos farmacias más.
  2. La tarjeta de ahorro de Keytruda Qlex solo funciona con un seguro del trabajo o uno que usted compró.

Otras opciones

Gratis del fabricante, si cumple los requisitos Merck Patient Assistance Program. You may qualify for the program if you have a household income of $63,840 or less for individuals, $86,560 or less for couples, or $132,000 or less for a family of 4. O llame al 800-727-5400.

Ver si cumple los requisitos 

Compare todas las opciones

De marca

Keytruda Qlex, el original

Sin seguroPregunte en la farmacia
Formas de ahorrar en Keytruda Qlex

La tarjeta del fabricante

Merck Co-pay Assistance Program (The Merck Access Program)

Tarjeta de ahorro de Merck

Sin seguroRequiere seguroNo tiene precio sin seguro.
Con seguro · desde $25 por dosis

La tarjeta descuenta hasta $25,000 al año de su copago.

Inscríbase en merckaccessprogram-keytruda.com 

O llame al 1-855-257-3932. Vea la oferta en merckaccessprogram-keytruda.com

En palabras del fabricante (en inglés)

“Once enrolled, eligible, privately insured patients pay the first $25 of their co-pay per administration…”

De la oferta del fabricante en merckaccessprogram-keytruda.com, revisada el 17 de noviembre de 2026. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.

¿Tarjeta del fabricante o tarjeta de descuento?

Una tarjeta de descuento como GoodRx baja el precio sin seguro de la farmacia, pero para un medicamento de marca ese precio muchas veces sigue siendo alto. Compárelo con la tarjeta del fabricante que aparece arriba. Por lo general, puede usar una u otra al surtir su receta, no las dos.

Genérico autorizado

No existe ninguno.

No se vendeNo existe ninguno

Genérico regular

Keytruda Qlex es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

No se vendePregunte en la farmacia

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated:

Melanoma

  • for the treatment of adult patients with unresectable or metastatic melanoma.
  • for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection.

Non-Small Cell Lung Cancer (NSCLC)

  • in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
  • in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of adult patients with metastatic squamous NSCLC.
  • as a single agent for the first-line treatment of adult patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is:
    • Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
    • metastatic.
  • as a single agent for the treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA QLEX.
  • for the treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
  • as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

Malignant Pleural Mesothelioma (MPM)

  • in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.

Head and Neck Squamous Cell Cancer (HNSCC)

  • for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
  • in combination with platinum and FU for the first-line treatment of adult patients with metastatic or with unresectable, recurrent HNSCC.
  • as a single agent for the first-line treatment of adult patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
  • as a single agent for the treatment of adult patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Urothelial Cancer

  • in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
  • as a single agent for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
    • are not eligible for any platinum-containing chemotherapy, or
    • who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  • in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC).
  • as a single agent for the treatment of adult patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

  • for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)

  • for the treatment of adult patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.

Gastric Cancer

  • in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
  • in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.

Esophageal Cancer

  • for the treatment of adult patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
    • in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or
    • as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

Cervical Cancer

  • in combination with chemoradiotherapy, for the treatment of adult patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA).
  • in combination with chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
  • as a single agent for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.

Hepatocellular Carcinoma (HCC)

  • for the treatment of adult patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.

Biliary Tract Cancer (BTC)

  • in combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer.

Merkel Cell Carcinoma (MCC)

  • for the treatment of adult and pediatric patients 12 years and older with recurrent locally advanced or metastatic Merkel cell carcinoma.

Renal Cell Carcinoma (RCC)

  • in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
  • in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
  • for the adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
  • in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Endometrial Carcinoma

  • in combination with carboplatin and paclitaxel, followed by KEYTRUDA QLEX as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
  • in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
  • as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Tumor Mutational Burden-High (TMB-H) Cancer

  • for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Cutaneous Squamous Cell Carcinoma (cSCC)

  • for the treatment of adult patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.

Triple-Negative Breast Cancer (TNBC)

  • for the treatment of adult patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
  • in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
  • in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

Ovarian Cancer

  • in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

Fuente: la etiqueta de la FDA de Keytruda Qlex (Merck Sharp & Dohme LLC), 16 de octubre de 2026. Etiqueta completa en DailyMed 

Datos útiles

  • “Seguro comercial” quiere decir un plan de su trabajo, del Mercado de Seguros Médicos o uno que usted compra por su cuenta. Un plan para jubilados que forma parte de Medicare cuenta como Medicare. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.
  • La mayoría de las tarjetas requieren inscribirse en el sitio web del fabricante, y muchas solo funcionan si su plan cubre el medicamento. Después, dé los datos de la tarjeta a su farmacia.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.